VALABREGA, Giorgio
 Distribuzione geografica
Continente #
NA - Nord America 5.454
EU - Europa 3.444
AS - Asia 2.111
AF - Africa 85
SA - Sud America 81
OC - Oceania 70
Continente sconosciuto - Info sul continente non disponibili 10
Totale 11.255
Nazione #
US - Stati Uniti d'America 5.298
CN - Cina 1.164
IT - Italia 1.000
GB - Regno Unito 370
IE - Irlanda 369
DE - Germania 330
SE - Svezia 278
FR - Francia 269
JP - Giappone 227
IN - India 135
ES - Italia 131
FI - Finlandia 120
KR - Corea 118
VN - Vietnam 116
CA - Canada 115
UA - Ucraina 109
PL - Polonia 104
SG - Singapore 88
AU - Australia 61
DK - Danimarca 59
NL - Olanda 58
BE - Belgio 48
TR - Turchia 48
HK - Hong Kong 43
MX - Messico 40
TW - Taiwan 39
BR - Brasile 37
CH - Svizzera 35
EG - Egitto 30
AT - Austria 27
RU - Federazione Russa 26
TH - Thailandia 25
IR - Iran 24
NG - Nigeria 23
PT - Portogallo 23
RO - Romania 21
IL - Israele 19
SA - Arabia Saudita 13
AR - Argentina 12
CO - Colombia 11
HR - Croazia 11
GR - Grecia 10
HU - Ungheria 10
PE - Perù 10
ID - Indonesia 9
NZ - Nuova Zelanda 9
UZ - Uzbekistan 9
CL - Cile 8
MY - Malesia 8
NO - Norvegia 7
AP - ???statistics.table.value.countryCode.AP??? 6
CZ - Repubblica Ceca 6
KW - Kuwait 6
MA - Marocco 6
SN - Senegal 6
TN - Tunisia 6
BY - Bielorussia 5
EU - Europa 4
PK - Pakistan 4
SD - Sudan 4
SK - Slovacchia (Repubblica Slovacca) 4
ZA - Sudafrica 4
AM - Armenia 3
BG - Bulgaria 3
EC - Ecuador 3
RS - Serbia 3
JO - Giordania 2
LB - Libano 2
MO - Macao, regione amministrativa speciale della Cina 2
PH - Filippine 2
UG - Uganda 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
CU - Cuba 1
EE - Estonia 1
ET - Etiopia 1
IQ - Iraq 1
IS - Islanda 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
QA - Qatar 1
SI - Slovenia 1
ZW - Zimbabwe 1
Totale 11.255
Città #
Chandler 626
Fairfield 448
Dublin 356
Houston 345
Beijing 338
Ashburn 327
Woodbridge 247
Ann Arbor 240
Seattle 213
Wilmington 186
Cambridge 170
Torino 155
Nyköping 137
Redwood City 127
Jacksonville 102
Shanghai 98
Princeton 91
Medford 90
Villeurbanne 86
Dearborn 85
Munich 80
New York 74
Guangzhou 71
Pisa 67
Warsaw 67
Milan 66
Dong Ket 64
Rome 64
Singapore 58
Turin 54
Nanjing 51
Tokyo 50
Boston 41
Fremont 41
London 38
Hangzhou 33
San Diego 29
Wuhan 28
Asyut 27
Chicago 27
Duncan 27
Los Angeles 26
Chengdu 25
Ottawa 25
Taipei 24
Toronto 23
Abuja 20
Brussels 19
Madrid 19
Delhi 18
Kunming 18
Jinan 17
Paris 17
Washington 17
Barcelona 16
Hefei 16
Helsinki 16
Silver Spring 16
Sydney 16
Vienna 16
Hebei 14
Phoenix 14
Seoul 14
Shenyang 14
Upper Marlboro 14
Dallas 13
Hong Kong 13
Istanbul 13
Osaka 13
Tianjin 13
Worcester 13
Boardman 12
Changsha 12
Norwalk 12
Riverton 12
Xian 12
Zhengzhou 12
Amsterdam 11
Ankara 11
Bangkok 10
Berlin 10
Düsseldorf 10
Glasgow 10
Gothenburg 10
Harbin 10
New Delhi 10
Newcastle 10
São Paulo 10
Valencia 10
Varese 10
Basingstoke 9
Birmingham 9
Central District 9
Changchun 9
Copenhagen 9
Florence 9
Malappuram 9
Naples 9
Qingdao 9
Rochester 9
Totale 6.330
Nome #
PARP Inhibitors in Ovarian Cancer 2.468
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 670
New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer 508
Metastatic breast cancer subtypes and central nervous system metastases. 282
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 240
Modeling ErbB2-p130Cas interaction to design new potential anticancer agents. 229
Checkpoint inhibitors in endometrial cancer: Preclinical rationale and clinical activity 216
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis 191
p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy 186
Androgen receptor status predicts development of brain metastases in ovarian cancers 184
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer 182
Adoptive immunotherapy against ovarian cancer 167
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy 165
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions 157
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer 152
Immune checkpoint inhibitors: A new opportunity in the treatment of ovarian cancer? 152
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. 145
Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer? 140
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience 123
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer 119
Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: A retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer 118
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers 116
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy 113
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience 110
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications 109
Abstract 3102: Identification of actionable cancer genes and treatment options for metastatic ovarian carcinomas using patient-derived xenografts and PDX-derived tumor cells 109
Reprogramming T-cells for adoptive immunotherapy of ovarian cancer 107
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy 105
The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005 104
Recent advances in the development of breast cancer vaccines. 102
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. 101
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature 100
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity 99
Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series 97
Immune checkpoint inhibitors in epithelial ovarian cancer: An overview on efficacy and future perspectives 95
Assays of conventional chemotherapeutics and targeted drugs for ovarian cancer using patient derived models 90
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma 89
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer 88
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib 86
Clinical implications of DNA repair defects in high-grade serous ovarian carcinomas 86
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer 83
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. 82
Ovarian cancer immunotherapy: Turning up the heat 81
Identification of Actionable Cancer Genes and Treatment Options for Metastatic Ovarian Carcinomas using Patient Derived Xenografts (PDXs) and PDX Derived Tumor Cells (PDTCs) 78
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy 73
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. TOP2A as marker of response to PLD in ovarian cancer 72
Role of cyclin-dependent kinase inhibitors in endometrial cancer 72
Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial 69
A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. 68
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report 66
Is there a role for immunotherapy in ovarian cancer? 65
Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience 65
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation 61
Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. 61
Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents (Scientific Reports, (2019), 9, 1, (3089), 10.1038/s41598-019-39510-w) 61
Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer 60
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study 60
Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007 59
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers 58
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 58
Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. 55
Veliparib: a new therapeutic option in ovarian cancer? 54
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21) 54
Controversies in breast cancer: adjuvant and neoadjuvant therapy 52
Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. 50
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era 49
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality 46
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey 44
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition 44
Translational research in ovarian cancer 43
Biomarkers of central nervous system involvement from epithelial ovarian cancer 43
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time? 43
Role of trastuzumab in the management of HER2-positive metastatic breast cancer. 42
Trastuzumab-based combination therapy for breast cancer 41
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) 40
Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. 40
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 39
Trastuzumab treatment in breast cancer 39
Immunotherapy in cervix cancer 39
Differences in parp inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy 39
Multitarget drugs: the present and the future of cancer therapy 38
Potential of afatinib in the treatment of patients with HER2-positive breast cancer. 38
From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia 38
Trastuzumab Beyond Disease Progression: Case Closed? 37
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors 37
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 37
Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells 36
ASO Visual Abstract: Clinical and Histopathologic Predictors Signaling Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 35
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer 35
Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. 30
Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? 30
Impact of covid-19 in gynecologic oncology: A nationwide italian survey of the sigo and mito groups 28
Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. 26
Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey 19
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study 17
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society 17
Correction: Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 16
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 16
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 15
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 10
Totale 11.503
Categoria #
all - tutte 27.869
article - articoli 0
book - libri 0
conference - conferenze 841
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.710


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019248 0 0 0 0 0 0 0 0 0 0 173 75
2019/20201.229 49 43 52 128 92 219 129 112 136 93 67 109
2020/20212.148 67 172 270 172 175 173 157 153 178 204 140 287
2021/20222.082 149 132 103 161 135 144 157 170 161 148 329 293
2022/20232.425 211 222 94 198 229 481 184 152 257 86 172 139
2023/20241.733 211 221 104 147 145 257 158 166 40 158 126 0
Totale 11.541